UCLA’s HIV prevention and treatment centre receives $7.5 million NIH grant
pharmafile | March 21, 2022 | News story | Sales and Marketing |
The National Institute of Mental Health has renewed its support for UCLA’s collaborative Centre for HIV Identification, Prevention and Treatment Services, or CHIPTS, with a five-year, $7.5 million grant. The new federal funding will support a research agenda aimed at reducing HIV transmission across Southern California, the US, and around the world.
This aligns with the US Department of Health and Human service’s initiative to end the epidemic in the US by 2030.
“The centre plays a critical role in advancing HIV prevention science that innovates in combination prevention strategies and shifts policy to influence health outcomes,” said CHIPTS co-director Dr Raphael Landovitz, a professor of medicine at the Geffen School. “We are extremely grateful for the opportunity to continue and expand our work in this next cycle.”
The centre is made up of leading scientists from UCLA, Charles R Drew University of Medicine and Science, the Friends Research Institute and the RAND Corp., and has worked for 25 years to combat the HIV/AIDS epidemic both locally and globally through scientific research and treatments, network building and collaborations with community and agency partners.
“This award is a testament to the unwavering commitment of our scientists and community partners,” said Steven Shoptaw, professor of family medicine and of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA. Shoptaw is also vice chair of research in family medicine at UCLA. “With this funding, we look forward to pursuing innovative, high-impact approaches to address the HIV epidemic and the conditions that drive it.”
The giant program will be directed by Shoptaw.
1.2 million in the US are living with HIV, with approximately 35,000 new cases diagnosed each year in the US, according to the CDC.